SWX:IDIABiotechs
Idorsia (SWX:IDIA) Valuation Check After Lucerastat Phase 3 Agreement With US And European Regulators
Idorsia (SWX:IDIA) is back on investors’ radar after securing regulator alignment in the US and Europe on a streamlined Phase 3 registration program for its Fabry disease candidate, lucerastat.
See our latest analysis for Idorsia.
The latest lucerastat update lands after a sharp swing in sentiment, with Idorsia’s 1 year total shareholder return very large at about 5.3x. However, the year to date share price return is slightly negative and longer term total shareholder returns over 3 and 5...